Market revenue in 2023 | USD 47.6 million |
Market revenue in 2030 | USD 71.1 million |
Growth rate | 5.9% (CAGR from 2023 to 2030) |
Largest segment | Inactivated (killed) |
Fastest growing segment | Other Vaccines (e.g. Recombinant, DNA, subunit, or toxoids) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Modified/ Attenuated Live, Inactivated (Killed), Other Vaccines (e.g. Recombinant, DNA, subunit, or toxoids) |
Key market players worldwide | Merck & Co Inc, CEVA Inc, Zoetis, Boehringer Ingelheim, Elanco Animal Health Inc, Indian Immunologicals, Biogenesis Bago, Phibro Animal Health Corp Class A, Virbac SA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to swine vaccines market will help companies and investors design strategic landscapes.
Inactivated (killed) was the largest segment with a revenue share of 39.92% in 2023. Horizon Databook has segmented the Australia swine vaccines market based on modified/ attenuated live, inactivated (killed), other vaccines (e.g. recombinant, dna, subunit, or toxoids) covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia swine vaccines market , including forecasts for subscribers. This country databook contains high-level insights into Australia swine vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account